


Exceptional service in the national interest




Active role of the substrate during catalysis by the therapeutic enzyme L-asparaginase II

Juan M. Vanegas, Andriy Anishkin (UMD), Sergei Sukharev (UMD), and Susan Rempe

Nanobiology Dept., Center for Biological and Material Sciences
Sandia National Laboratories

L-Asparaginase: Starving cancer cells


- *E. coli* L-ASP deamidates Asn and Gln




- L-ASP in bloodstream starves certain cancer cells that are auxotrophic for Asn
- Large catalytic difference for Asn vs Gln degradation despite only one CH₂ difference
- L-ASP has been used to treat acute lymphoblastic leukemia for 40+ years – yet complete reaction mechanism remains unknown!!

L-ASP structure and function

- Homotetramer – active site at interface between two subunits
- Two threonines identified as possible nucleophiles – T12 and T89
 - T89V and T12A single mutants both reduce k_{cat} ~100,000 fold
 - T89V forms covalently bound acyl-enzyme dead-end state with substrate (crystal structure)
- K162 mutants also reduce k_{cat}
 - May have unusually low pK_a – proton shuttle?
- Y25 suggested as possible proton shuttle to E283 during nucleophilic attack
 - E283 mutations show little change in k_{cat}




X-ray structure with Asp ligand




Substrates and kinetics

- L-ASP can catalyze many substrates
 - Asn analogs such as succinamate and small peptides with carboxy-terminal Asn – absolute requirement of carboxyl 2-3 carbons from amide




- Kinetic studies support a double displacement mechanism – NH₃ is cleaved first followed by H₂O nucleophilic attack




L-ASP crystal structure


- Proposed L-ASP reaction mechanisms have been based on crystal structure with final ****Asp product****
- Hydrogen bonding geometry suggests unusual protonation of α -carboxyl (H-bonded to S58)
- Classical MD simulations with Asp product in different protonation states (protein backbone restrained)




X-ray structure
with Asp ligand




Unprotonated carboxyls
Contacts RMSD 0.601
Ligand RMSD 0.625



α -COOH
Contacts RMSD 0.446
Ligand RMSD 0.178




γ -COOH
Contacts RMSD 0.413
Ligand RMSD 0.919



α -COOH and γ -COOH
Contacts RMSD 0.449
Ligand RMSD 0.304


L-ASP with natural substrates

- Asn substrate quickly rearranges in L-ASP active site
 - T12, S58 and T89 “clamp” onto oxygens of Asn




Probability of finding heavy atoms within 3 Å

	ASN				GLN			
	Lig. 1	Lig. 2	Lig. 3	Lig. 4	Lig. 1	Lig. 2	Lig. 3	Lig. 4
T12-OH---O _{α1}	0.53	0.91	0.96	0.68	0.00	0.98	0.96	0.00
T12-NH---O _{α1}	0.92	0.87	0.89	0.63	0.00	0.07	0.58	0.00
S58-OH---O _{α2}	0.99	0.99	0.99	0.66	0.96	0.52	0.99	0.49
S58-NH---O _{α2}	0.86	0.85	0.91	0.02	0.96	0.00	0.75	0.59
Q59-O---HN _α	0.78	0.80	0.78	0.02	0.44	0.00	0.91	0.30
Q59-NH---O _{α2}	0.00	0.00	0.00	0.00	0.26	0.00	0.00	0.29
T89-OH---O _{γ(δ)}	0.50	0.83	0.40	0.53	0.00	0.29	0.01	0.00
T89-NH---O _{γ(δ)}	0.89	0.86	0.82	0.50	0.00	0.69	0.56	0.00
D90-O---HN _α	0.99	0.99	0.99	0.98	0.99	0.91	0.99	0.97
A114-O---HN _{γ(δ)}	0.59	0.57	0.50	0.60	0.57	0.04	0.00	0.31
E283-O ₁ ---HN _α	0.95	0.82	0.74	0.72	0.28	0.00	0.00	0.66
E283-O ₂ ---HN _α	0.29	0.58	0.69	0.76	0.21	0.00	0.00	0.65
HOH---O _{α1}	0.77	0.69	0.41	0.53	0.00	0.06	0.00	0.08
HOH---O _{γ(δ)}	0.12	0.09	0.42	0.33	0.96	0.00	0.00	0.67
Q59-NH---O ₁ -E283	0.31	0.37	0.11	0.00	0.02	0.01	0.00	0.00
K162-NH---OH-T89	0.91	0.92	0.89	0.87	0.19	0.00	0.00	0.21
K162-NH---O ₂ -D90	1.00	1.00	1.00	0.96	1.00	0.07	0.99	1.00
N248-NH---O ₁ -D90	0.34	0.24	0.32	0.04	0.05	0.18	0.00	0.00
N248-NH---O ₁ -E283	0.19	0.08	0.25	0.32	0.08	0.02	0.01	0.24
N248-NH---O ₂ -E283	0.37	0.51	0.27	0.24	0.14	0.04	0.02	0.20
A114-NH---OH ₂	0.97	0.99	0.99	0.98	1.00	0.93	0.99	0.81
L13-NH---OH ₂	0.99	0.98	0.97	0.84	1.00	1.00	1.00	0.41




Testing initial stages of reaction

- Test direct nucleophilic attack by T12 onto γ -carbon of Asn
 - Use *ab initio* MD to look at kinetics + single point energy calculations
 - QM system includes nearby protein residues + waters – 239 atoms
 - α -carbons fixed in order to maintain structure of active site




Direct nucleophilic attack by T12

- Nucleophilic attack is driven by constraining distance between atoms and slowly reducing the distance
- PBE functional + vdW-DF2 dispersion correction (NVT, dt=0.5ps)



Direct nucleophilic attack by T12


- T12 hydroxyl proton spontaneously transferred to α -carboxyl
- Enzyme-substrate covalent intermediate unstable
- What about single point energies?
 - Optimized end states with B3LYP functional and 6-31G(d) basis set
 - Single point calculations with M062X and ω B97X-D functionals and 6-311G++(2d,2P) basis set



$$\Delta E (\text{M062X}) = 28 \text{ kcal/mol} // \Delta E (\omega\text{B97X-D}) = 32 \text{ kcal/mol}$$



Pre-protonation by K162-T89

- Tetrahedral intermediate may be stabilized by first protonating amide oxygen through K162-T89 proton bridge





α -COOH – S58 hydrogen bonding

- Protonated α -COOH may prefer a “paired” hydrogen bonding pattern with S58 instead of a “clamp”




ΔE (M062X) = -6 kcal/mol
 ΔE (ω B97X-D) = -6 kcal/mol



ΔE (M062X) = -6 kcal/mol
 ΔE (ω B97X-D) = -7 kcal/mol

T89V mutant crystal structure

- E-AsnH' configuration resembles the acyl-enzyme intermediate present in the T89V crystal structure (PDB 4ECA)



- WT + T89V crystal structures may provide details of intermediates, not initial substrate orientation

Ongoing work

- Use QM/MM approach to allow better optimization of structures
- Determine energetic barriers using freezing string method – typical transition state search methods fail due to # of DOF
- Test nucleophilic attack by T89 and possible subsequent steps
- References:
 - Anishkin, A., **Vanegas, J. M.**, Rogers, D. M., Lorenzi, P. L., Chan, W. K., Purwaha, P., Weinstein, J. N., Sukharev, S., and Rempe, S. B. Catalytic Role of the Substrate Defines Specificity of Therapeutic L-Asparaginase. *J. Mol. Biol.* DOI: 10.1016/j.jmb.2015.06.017 (2015)
 - Chan, W. K. *et al.* The Glutaminase Activity Of L-Asparaginase Is Not Required For Anticancer Activity Against Asns-Negative Cell Lines. *Blood* 123, 3596–3606 (2014).

Acknowledgments

- Our external collaborators:
 - University of Maryland – Sergei Sukharev, Andriy Anishkin
 - MD Anderson Cancer center – Phillip Lorenzi, John Weinstein
- Funding
 - Sandia LDRD (Laboratory Directed Research and Development)
 - Defense Threat Reduction Agency